Published in final edited form as:

Anticancer Drugs. 2012 March ; 23(3): 272–279.

Identification of unique synergistic drug combinations associated with down expression of survivin in a preclinical breast cancer model system

Daniel R. Budman^{a,c}, Anthony Calabro^{a,c}, Lisa Rosen^{b,c}, and Martin Lesser^{b,c}

^aSection of Experimental Therapeutics, Don Monti Division of Oncology, Monter Cancer Center, 450 Lakeville Road, Lake Success, New York 11042 USA

^bThe Department of Biostatistics, 450 Lakeville Road, Lake Success, New York 11042 USA

^cFeinstein Institute, 450 Lakeville Road, Lake Success, New York 11042 USA

Summary

An in vitro 72 hour assay using median effect analysis and curve shift analysis was employed to evaluate the utility of potentially clinically useful combinations of agents for synergism or antagonism. Six human breast cancer cell lines both receptor rich and receptor poor were studied. Panobinostat (LBH-589), a pan histone deacetylase inhibitor with a multitude of biological effects, exhibits time dependent synergistic effects in breast cancer cell lines with docetaxel, doxorubicin, or gemcitabine in clinically relevant concentrations. Survivin expression was markedly down regulated in the presence of panobinostat with gemcitabine. Bortezomib, a proteasome inhibitor, markedly enhanced the cytotoxic effects of panobinostat combined with gemcitabine. Panobinostat did not demonstrate universal enhancement of cytotoxic drugs, and therefore synergy was dependent upon the second agent selected. No synergy was noted with anti Her2 agents in Her2 over expressing cell lines. Metformin combined with panobinostat demonstrated no synergy in this test system. These effects were confirmed by apoptosis assay and caspase-3 production. A positive drug interaction was identified. The triplet of panobinostat with either doxorubicin / carboplatin or gemcitabine / carboplatin was especially potent in all cell lines. As all these agents are clinically available, further studies of the potent combinations are warranted.

Keywords

synergism; breast cancer; therapy; survivin; combination; in vitro

Introduction

In United States, the incidence of breast cancer has dropped over the last decade but still remains a major source of morbidity and mortality [1]. In turn, the use of pharmacological treatment of this disease has slowly improved but the majority of women with relapsed or

Address correspondence to D.R. Budman, MD, Monter Cancer Center; budman@nshs.edu. Tel: 516-734-8958; Fax 516-734-8924.

Conflicts of interest: none

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

disseminated disease ultimately still expire from this disease [2]. Therefore, new approaches with therapeutic intent are needed

One recent approach has been to combine classical cytotoxic agents with biologics or small molecules which perturb signal pathways or enhance apoptosis. This approach has been most successful in the use of trastuzumab in Her2/neu over expressing breast cancer although drug resistance occurs [3, 4]. As a consequence of “proof of principle”, numerous agents have been developed to interfere with cellular pathways. Many of these agents are currently under clinical evaluation. In addition, recent preclinical findings suggest that many of the small molecules perturb the cell through a variety of mechanisms and are not as specific as originally thought. We have been interested in small molecules which perturb several cell functions. One such group of agents is the non selective histone deacetylase inhibitors such as panobinostat [5] which have numerous on and off target effects including enhancement of endoplasmic stress in the tumor cell leading to apoptosis [6], interference with histone deacetylase 6 function which plays a critical role in both oncogenic transformation and the ability of the transformed cell to form an intact tumor [7], inhibition of heat shock protein 90 chaperone function [8], protein degradation [9], and perturbation of aggresome function [10]. In a human colon cancer cell line (HCT116p21+), survivin levels were also reduced in the presence of a non selective histone deacetylase inhibitor [11]. Survivin has been implicated as a major drug resistance factor in the MDA-MB 231 breast cancer cell lines by using siRNA interference [12] and causes primary resistance to trastuzumab in Her2+ lines [13, 14]. In preclinical myeloma models, application of panobinostat with bortezomib resulted in interference with the aggresome function and with histone 6 deacetylase function causing a marked increase in tumor cell death [15, 16].

We have been interested for several years in using a semi automated model in vitro system to screen for synergism and antagonism of clinically available drugs to make drug combinations more rational [17–21]. This non biased screening approach is based upon the finding of unexpected interactions between agents when combined [22] and the ability of multi targeted agents to exhibit synergistic effects [23]. This assay does not presume that a specific pathway is responsible for anticancer effects and thus is adaptable to drugs known to cause multiple perturbations of cell function. This short in vitro assay allows up to three agents to be studied in combination and also allows scheduling of agents to be examined. If a positive result is identified, further studies on the potential mechanism of action can be initiated. Recently, using this approach we identified marked synergy between a pan histone deacetylase inhibitor, panobinostat, and gemcitabine in ovarian carcinoma cell lines [21]. We therefore report our findings in breast cancer cell lines with panobinostat, classical cytotoxic agents, a proteasome inhibitor, and metformin which has assumed prominence in the clinical trials program [24, 25]. Metformin had previously been demonstrated to enhance taxane cytotoxicity in a murine xenograft model [26]. We herein demonstrate that the panhistone deacetylase inhibitor, panobinostat, does indeed reduce survivin levels in human breast cancer cell lines and that this effect is associated with enhancement of cytotoxicity with several classical therapeutic agents.

Materials and Methods

The human breast cancer cell lines MCF7/wt, BT474, SK-BR-3, and HTB25 were obtained from the American Tissue Culture Collection (ATCC, Rockville, MD, USA). MCF7/adr (a multiply drug resistant line grown in the presence of doxorubicin) was obtained from the NCI as a gift from Dr. Kenneth Cowan, and HCC1395 from Dr. John Minna, University of Texas -- Dallas. DU145 is a prostate cancer cell line obtained from ATCC used as a negative control. MCF7/wt and BT 474 express the estrogen receptor; SK-BR-3 and MCF7/adr are receptor negative and over express Her2/neu [27]. HTB-25 and HCC1395 are triple negative

variants [27, 28]. The phenotypes of these cell lines were re-assayed using a quantitative Elisa method as discussed below as phenotypic drift may occur in cell lines [29].

Panobinostat (LBH-589) and fluvastatin were gifts from Novartis Pharmaceuticals (East Hanover, NJ, USA); Docetaxel was a gift of Sanofi-Aventis Corporation (Bridgewater, NJ, USA). GW282974X (an analogue of lapatinib) was supplied by Glaxo SmithKline (Philadelphia, PA, USA). The following agents were obtained from Sigma-Aldrich (St. Louis, MO, USA): carboplatin, docetaxel, doxorubicin, 5'DFUR (metabolite of capecitabine), and paclitaxel. Bortezomib, gemcitabine, topotecan, and trastuzumab were obtained from commercial stock.

The various cell lines were grown to confluence in T-150 tissue culture flasks (Corning Glass Works, Corning, NY) using RPMI 1640 media (Invitrogen, Carlsbad, CA) with 10% heat inactivated fetal calf serum and 5% CO₂. Cells were then re-plated into 96 well dishes (Falcon 3072) at concentrations of 5000 cells per well and grown in exponential phase. Drug or solvent control was then added and the cells incubated for 72 hours. No sequential studies of agents were done. For triplet studies containing clinically achievable levels of metformin (1.0 μ M), the metformin concentration was held as a constant and not varied during the determination of the dose response curve. An identical procedure for bortezomib was followed at 0.26 μ M which is the clinically achievable concentration.

Cell death was identified by MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide assay [30] and read at 595 nm on a BioRad 3550 MicroPlate Reader. We had previously compared this assay to Trypan blue exclusion with concordant results [17]. For determination of the IC₅₀ (the concentration required for 50% growth inhibition) a dose response curve of a given agent applied for 72 hours was analyzed by the EZ ED₅₀ program (Perrella Scientific, Conyers, CA) and extrapolated from the curve with all values the means of 3 to 4 experiments. For median effect isobologram analysis [31], 10 fixed drug ratios above and below the IC₅₀ of the combination were done to identify the dose response curve as previously described [32]. Fa is defined as the fraction of cells affected and a plot of log dose vs. log (Fa/1-Fa) gives parallel slopes of no biologic interaction is present (mutually exclusive) or converse if there is an interaction between the drugs (mutually non-exclusive). This plot suggested that the non exclusive criteria should be used. The data was therefore analyzed by using the non-exclusive criteria and the computer program of Chou [33]. CI (combination index) values were determined at Fa₅₀ (50% effect) as the method is a linear approximation of a non linear process and most accurate at Fa₅₀ [34]. CI values less than unity are synergistic effects, unity additive, and greater than unity antagonistic. Assays were usually done in triplicate to determine standard deviation. Results were confirmed by curve shift analysis which normalizes concentrations using the program ACT Analysis (Optimum Therapeutics, Columbus, Ohio) [35].

Apoptosis was measured by the Cell Death Detection ELISApplus kit (Roche Applied Science, Penzberg, Germany) using the manufacturer's directions. This method detects 5-bromo-2'-deoxyuridine labeled fragmented DNA. The resulting enrichment factor is defined as the relative fold increase in apoptosis as measured by optical density compared to the control as calculated by the formula: mU of dying or dead cells/mU of untreated cells where mU = absorbance 405nm–490nm. Quantification of total Caspase-3 protein was performed using the Genscript® Total Caspase-3 colorimetric assay Kit (Cat # L00289) Sandwich ELISA kit (GeneScript, Inc.; www.genscript.com) was done as per manufacturer's instructions. The method is based on a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of Caspase-3. The Survivin ELISA kit was obtained from Calbiochem (www.calbiochem.com, La Jolla, California, USA Cat # CBA048). Reactions were measured at 450 nm in a manner analogous to MTT. Human

recombinant Caspase-3 protein (Cat # 10-663-46608), human recombinant ER protein (Cat #10-786-259004), human recombinant PR protein (10-786-259007), and human recombinant Her2/neu protein (Cat # 10-511-248341) were all obtained from GenWay Biotech, Inc (www.genwaybio.com, San Diego, California, USA) and were used to generate a standard curve for protein assays with a Lowry protein assay kit (Sigma-Aldrich, www.sigmaaldrich.com, St. Louis, Missouri, USA). Results were read at 595 nm. ER (Cat # 49296) and PR (Cat #49396) sandwich ELISA kits were obtained from Active Motif (www.activemotif.com, Carlsbad, California, USA) and assays were done as per manufacturer's instructions. Total Her2/neu Sandwich ELISA was obtained from Cellsignal (Cat #7310 www.cellsignal.com, Danvers, Massachusetts, USA) using manufacturer's instructions.

Statistical Methods

For analysis of doublet combinations, the study was a 2×2 X 4 factorial design. Three way analysis of variance (ANOVA) with interaction terms was used to compare pictograms of caspase-3 and in identical manner survivin across treatment groups and time. The three factors were panobinostat, docetaxel, and time for the caspase-3 analysis and panobinostat, gemcitabine, and time for the survivin analysis. Caspase-3 was log-transformed in order to meet the standard assumptions of Gaussian residuals and equality of variance. Summary statistics are presented on the untransformed data for ease of interpretation. Standard deviation was calculated where applicable.

Results

As cell lines can genetically drift from their original origin [29], we first rephenotyped our cell lines using a quantitative ELISA assay (Figure 1). BT 474 and MCF₇wt are estrogen and progesterone receptor rich while MCF₇/adr, SK-BR-3, HTB-25, and HCC-1395 are receptor poor. BT 474, MCF₇/adr, and SK-BR-3 have high expression of Her2/neu. The DU 145 is a negative human prostate cancer control.

The IC₅₀ of each agent in the various cell lines is shown in Table 1. All results are for a 72 hour exposure of drug. The most active agent in this system is doxorubicin. Doublets of panobinostat with other agents were then tested in the 72 hour incubation with the median effect results (CI) reported at Fa₅₀ (Table 2). Panobinostat generated synergistic to additive effects in the majority of cell lines with most of the agents. Of interest, panobinostat was markedly synergistic with doxorubicin or with docetaxel in the receptor poor cell lines. Fluvastatin, an inhibitor of prenylation, which was active in some of our previous studies [32] did not demonstrate additional benefit in this study. In the Her2/neu rich cell lines, panobinostat did not synergize with either a tyrosine kinase Her2/neu inhibitor (GW282974X) or with trastuzumab. The p53 mutant cell line, BT 474, demonstrated the greatest resistance to sensitizing effects with panobinostat. Triplet combinations were also evaluated (Table 3). In contrast to the doublets, most of the triplet combinations revealed synergistic activity with panobinostat / doxorubicin / carboplatin and panobinostat / gemcitabine / carboplatin demonstrating the most synergism. A typical curve shift analysis confirming this synergistic cytotoxic effect is shown for SK-BR3 cells in Figure 2. In addition, bortezomib at clinically achievable concentrations in combination with either gemcitabine or as a triplet with gemcitabine and panobinostat exhibited marked synergistic cytotoxic effects in the receptor poor / her 2 negative HCC-1395 cell line (Figure 3). The CI for the entire Fa of the triplet panobinostat, gemcitabine, bortezomib is shown in Figure 3B. Figure 3C is the CI vs. Fa curve for panobinostat, doxorubicin, carboplatin demonstrating synergy. In contrast, the addition of metformin at clinically achievable concentrations did not enhance panobinostat doublet combinations (data not shown).

To determine whether or not the synergistic effects were time dependent, SK-BR-3 cells were exposed to single agent, control (media), panobinostat, docetaxel, or panobinostat with docetaxel for 24, 48, or 72 hours (Figure 4). As measured by the ELISA apoptosis assay, the combination of panobinostat with docetaxel demonstrated marked enhancement of cytotoxic effect and this effect was time dependent. Caspase-3 was also measured to show that this effect was due to apoptosis (Figure 5). The expression of survivin in the presence or absence of panobinostat, gemcitabine, or the combination over time was examined as shown in Figure 6. All drugs lowered survivin with the doublet of gemcitabine and panobinostat demonstrating marked effects (5 per cent of control at 3 days). This effect was rapid occurring within the first 24 hours of drug exposure.

ANOVA analysis demonstrated that there were indirect pharmacodynamic effects with a significant three-way interaction between panobinostat, docetaxel, and time ($p < 0.0001$). In the caspase-3 studies, a significant interaction ($p < 0.0001$) was noted by day 1 (supplemental figure A) with panobinostat in the presence of docetaxel increasing caspase-3 by 14%. No interaction was identified at day 2 ($p < 0.53$) but there were significant effects by day 3 ($p < 0.0001$). Three way analysis of panobinostat, gemcitabine, and time (supplemental Figure B) indicated a significant interaction ($p < 0.0001$). At day 1, the effect of gemcitabine was to decrease survivin by 62% while the panobinostat / gemcitabine combination decreased survivin by 87%. The effect of incubation time on drug effect was seen in a similar manner on days 2 ($p < 0.0001$) and day 3 ($p < 0.0001$) with a 86% decrease in survivin for the two drug combination.

Conclusions

Recent progress in cellular physiology has demonstrated that cellular pathways have complex interactions which when perturbed exhibit redundant mechanisms for survival [36]. Hence, targeting of a specific over expressed protein in a malignant cell may not result in an optimal outcome except for instances such as Her2 over expression in breast cancer or BCR-Abl expression in chronic myelogenous leukemia. In addition, small molecules may have off target effects which may be clinically more interesting [22]. Recently, the utility of defined cell lines has been re-emphasized to be useful in drug development [37].

Using our short term culture assay for synergism or antagonism, we have identified that the pan histone deacetylase inhibitor, panobinostat, exhibits time dependent synergistic effects with classical agents such as docetaxel or doxorubicin, especially in receptor poor breast cancer cells, and has enhanced effects when combined as a triplet with either doxorubicin / carboplatin or gemcitabine / carboplatin. The effect of panobinostat involves apoptosis as measured by ELISA assay and is time dependent with increasing effects with longer exposure duration. Survivin, a major anti-apoptotic protein is normally increased by noxious insults such as chemotherapy [38] and thus also studied in these experiments. Previous studies in a colon cancer cell line had demonstrated that histone deacetylase inhibition is associated with survivin down regulation [11], and we now demonstrate that this effect occurs in human breast cancer cells. This effect is enhanced when panobinostat is combined with gemcitabine. Furthermore, we have shown that in a receptor poor human breast cancer cell line, the addition of bortezomib, a clinically used proteasome inhibitor, to panobinostat and gemcitabine results in marked anti tumor effect in vitro. A previous preclinical study using a different pan histone deacetylase inhibitor, suberoylanilide hydroxamic acid, with a different proteasome inhibitor also enhanced cell death [39] but did not explore the effects when combined with classical chemotherapeutic agents.

These findings have potential clinical import. Bortezomib has already been combined with docetaxel in a phase I/II study of patients with breast cancer with evidence of activity [40].

Histone deacetylase inhibitors have been combined with chemotherapeutic agents in several tumors in preclinical models with activity noted when combined with gemcitabine [41, 42] but with a negative trial in humans with pancreatic cancer [43]. Other doublets and triplets, especially with a proteasome inhibitor have not been reported in patients with breast cancer. These results suggest that the type of tumor, the chemotherapeutic agent employed, the histone deacetylase inhibitor chosen, and perhaps the schedule of administration may be critical for clinical outcome.

In our studies, the use of panobinostat did not enhance the cytotoxic effects of all chemotherapeutic agents tested and did show some variation with cell line. In addition, the current experiments were done on a model system which does not take into account distribution of drug, metabolism, and therapeutic index. However, the present results, especially in receptor poor tumors, suggest that further investigation is warranted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported in part by NCI CA 35279

References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin.* 2010; 60:277–300. [PubMed: 20610543]
2. Autier P, Hery C, Haukka J, et al. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. *J Clin Oncol.* 2009; 27:5919–5923. [PubMed: 19884547]
3. Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? *Eur J Cancer.* 2008; 44:2781–2790. [PubMed: 19013786]
4. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. *Lancet Oncol.* 2009; 10:1179–1187. [PubMed: 19959074]
5. Beckers T, Burkhardt C, Wieland H, et al. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. *Int J Cancer.* 2007; 121:1138–1148. [PubMed: 17455259]
6. Di Fazio P, Schneider-Stock R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. *Cell Oncol.* 2010; 32:285–300. [PubMed: 20208142]
7. Lee YS, Lim KH, Guo X, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. *Cancer Res.* 2008; 68:7561–7569. [PubMed: 18794144]
8. Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. *Clin Cancer Res.* 2007; 13:4882–4890. [PubMed: 17699868]
9. Schrupp DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. *Clin Cancer Res.* 2009; 15:3947–3957. [PubMed: 19509170]
10. Simms-Waldrup T, Rodriguez-Gonzalez A, Lin T, et al. The aggresome pathway as a target for therapy in hematologic malignancies. *Mol Genet Metab.* 2008; 94:283–286. [PubMed: 18472289]
11. Nawrocki ST, Carew JS, Douglas L, et al. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. *Cancer Res.* 2007; 67:6987–6994. [PubMed: 17638911]

12. Montazeri Aliabadi H, Landry B, Mahdipoor P, Uludag H. Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. *Molecular Pharmaceutics*. 2011; 8:1120–1131. [PubMed: 21619051]
13. Oliveras-Ferraro C, Vazquez-Martin A, Cufi S, et al. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. *Biochemical and Biophysical Research Communications*. 2011; 407:412–419. [PubMed: 21402055]
14. Papanikolaou V, Iliopoulos D, Dimou I, et al. Survivin regulation by HER2 through NF-kappaB and c-myc in irradiated breast cancer cells. *Journal of Cellular and Molecular Medicine*. 2011; 15:1542–1550. [PubMed: 20716114]
15. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. *Blood*. 2006; 108:3441–3449. [PubMed: 16728695]
16. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. *Proc Natl Acad Sci U S A*. 2005; 102:8567–8572. [PubMed: 15937109]
17. Budman DR, Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. *Oncology*. 2006; 70:147–153. [PubMed: 16645328]
18. Budman DR, Calabro A, Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. *Anticancer Drugs*. 1998; 9:697–702. [PubMed: 9823428]
19. Budman DR, Calabro A, Kreis W. In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials? *Leukemia*. 2001; 15:1517–1520. [PubMed: 11587208]
20. Budman DR, Soong R, Calabro A, et al. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. *Anticancer Drugs*. 2006; 17:921–928. [PubMed: 16940802]
21. Budman DR, Tai J, Calabro A, John V. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. *Invest New Drugs*. 2011; 29:1124–1129.
22. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. *Proc Natl Acad Sci U S A*. 2003; 100:7977–7982. [PubMed: 12799470]
23. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. *Drug Discov Today*. 2007; 12:34–42. [PubMed: 17198971]
24. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Mol Cancer Ther*. 2010; 9:1092–1099. [PubMed: 20442309]
25. Martin-Castillo B, Dorca J, Vazquez-Martin A, et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. *Ann Oncol*. 2010; 21:187–189. [PubMed: 19884247]
26. Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. *Clinical cancer Research*. 2011; 17:3993–4005. [PubMed: 21543517]
27. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. *Breast Cancer Res Treat*. 2004; 83:249–289. [PubMed: 14758095]
28. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell*. 2006; 10:515–527. [PubMed: 17157791]
29. Osborne CK, Hobbs K, Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. *Breast Cancer Res Treat*. 1987; 9:111–121. [PubMed: 3620713]
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983; 65:55–63. [PubMed: 6606682]
31. Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res*. 2010; 70:440–446. [PubMed: 20068163]

32. Budman DR, Tai J, Calabro A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. *Breast Cancer Res Treat.* 2006; 104:93–101. [PubMed: 17004104]
33. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. *Pharmacol Rev.* 2006; 58:621–681. [PubMed: 16968952]
34. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. *Pharmacol Rev.* 1995; 47:331–385. [PubMed: 7568331]
35. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. *Clin Cancer Res.* 2004; 10:7994–8004. [PubMed: 15585635]
36. Berg EL, Kunkel EJ, Hytopoulos E. Biological complexity and drug discovery: a practical systems biology approach. *Syst Biol (Stevenage).* 2005; 152:201–206. [PubMed: 16986261]
37. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. *Nat Rev Cancer.* 2010; 10:241–253. [PubMed: 20300105]
38. Altieri DC. Validating survivin as a cancer therapeutic target. *Nat Rev Cancer.* 2003; 3:46–54. [PubMed: 12509766]
39. Domingo-Domenech J, Pippa R, Tapia M, et al. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. *Breast Cancer Res Treat.* 2008; 112:53–62. [PubMed: 18064564]
40. Awada A, Albanell J, Canney PA, et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. *Br J Cancer.* 2008; 98:1500–1507. [PubMed: 18454159]
41. Ellis L, Pili R. Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. *Pharmaceuticals (Basel).* 2010; 3:2411–2469. [PubMed: 21151768]
42. Kanzaki M, Kakinuma H, Kumazawa T, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. *Oncol Rep.* 2007; 17:761–767. [PubMed: 17342312]
43. Richards DA, Boehm KA, Waterhouse DM, et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. *Ann Oncol.* 2006; 17:1096–1102. [PubMed: 16641168]

Figure 1. Quantitative expression of phenotype using an ELISA assay. DU 145 is a negative control prostate cell line. Error bars are standard deviation.

Figure 2. Drug concentrations are normalized with cytotoxic effect measured at 72 hours of incubation. Shift to the left indicates synergy as is shown for the triplet combination.

Figure 3.

The IC₅₀ of single agent gemcitabine is enhanced in the presence of bortezomib in the receptor poor HCC-1395 breast cancer cell line (3A) with marked synergy (red line) of the triplet (panobinostat, gemcitabine, bortezomid) in HCC-395 cells as demonstrated by the CI curve (3B). 3C demonstrates synergy (red line) with panobinostat, doxorubicin, and bortezomab.

Figure 4. Time dependent apoptotic effects of panobinostat with or without docetaxel in vitro in SK-BR-3 cells. Standard deviation is shown by the error bars. Enrichment factor is the relative fold increase in 5-bromo-2'-deoxy-uridine DNA fragments compared to control.

Figure 5. Apoptotic effect as measured by caspase-3 formation. Error bars indicate standard deviation.

Figure 6. Profound down expression of survivin when panobinostat is combined with gemcitabine. SK-BR-3 cells were exposed to drug for 72 hours. Error bars are standard deviation.

Table 1

IC₅₀ of the various agents incubated for 72 hours in the six human breast cancer cell lines.

Drug	MCF ₇ /wt	MCF ₇ /adr ⁺	BT-474	SK-BR-3	HCC-1395	HTB-25
Bortezomib	0.2±0.0	0.2±0.0	0.4±0.0	0.2±0.1	0.1±0.0	0.1±0.0
Carboplatin	87.9±14.9	44.1±8.8	31.0±4.7	37.3±10.9	24.5±5.2	41.9±13.6
5'-Deoxy-5-fluorouridine	6.0±0.6	5.5±2.5	22.9±4.3	36.6±14.5	12.3±1.2	18.6±4.6
Docetaxel	14.9±2.1	3.00±0.5	33.1±19.3	8.0±0.4	22.4±5.5	44.9±7.4
Doxorubicin	0.005±0.001	49.4±7.4	0.3±0.0	1.1±0.3	2.3±0.9	0.3±0.1
Fluvastatin	34.2±5.7	5.3±1.5	23.2±7.7	57.7±7.7	75.8±4.6	33.4±2.9
Gemcitabine	2.3±0.5	2.9±1.3	7.7±1.3	1.9±0.1	63.0±8.4	13.8±6.2
GW282974X	7.6±1.8	6.8±1.5	4.8±1.7	0.6±0.1	1.5±0.2	29.7±7.6
Paclitaxel	18.7±3.8	20.5±1.0	32.8±9.5	42.4±5.4	87.7±15.0	33.8±3.7
Panobinostat	27.9±3.2	2.1±0.9	23.2±4.7	24.4±5.0	102.9±9.0	122.1±23.3
Topotecan	28.2±7.5	12.3±0.4	15.5±1.7	26.8±2.2	34.9±4.6	45.8±2.4
Trastuzumab	4.7±1.6	1.2±0.3	3.0±0.8	7.2±1.1	0.4±0.01	3.5±0.2

Concentrations are in μ M with the means $\pm$ standard deviation of 3–5 determinations.

Table 2

CI results at Fa₅₀ for 72 hour incubation.

COMBINATION	MCF7/wt	MCF7/adr ⁺	BT474	SK-BR-3	HCC-1395	HTB-25
Mutually Non-Exclusive	CI-50	CI-50	CI-50	CI-50	CI-50	CI-50
Panobinostat+Carboplatin	0.7±0.0	0.8±0.1	0.6±0.1	0.4±0.1	0.5±0.1	0.8±0.1
Panobinostat+5'-DFUR	0.3±0.1	0.9±0.1	1.0±0.0	0.8±0.1	0.8±0.1	0.4±0.0
Panobinostat+Doxorubicin	1.6±0.2	0.6±0.1	0.9±0.0	0.3±0.1	0.3±0.0	0.5±0.1
Panobinostat+Docetaxel	0.9±0.1	0.4±0.0	0.3±0.1	0.3±0.1	2.0±0.1	0.5±0.1
Panobinostat+Fluvastatin	2.0±0.1	1.0±0.4	1.0±0.2	1.8±0.1	1.3±0.3	0.7±0.2
Panobinostat+Gemcitabine	0.4±0.1	0.9±0.0	1.3±0.1	0.6±0.1	0.4±0.1	0.8±0.1
Panobinostat+GW282974X	1.1±0.3	0.6±0.0	1.7±0.1	1.6±0.2	0.9±0.1	0.7±0.1
Panobinostat+Paclitaxel	0.7±0.1	0.9±0.1	1.2±0.2	0.8±0.1	1.2±0.1	0.5±0.1
Panobinostat+Topotecan	1.1±0.1	1.0±0.2	1.0±0.1	0.4±0.1	0.9±0.2	0.8±0.2
Panobinostat+Trastuzumab	1.0±0.4	0.7±0.1	1.6±0.2	1.6±0.2	0.6±0.1	0.6±0.1

CI < 1 are synergistic (green), 1 additive (blue), > 1 antagonistic (red). Values are means of studies ± standard deviation. 5'DFUR is 5'deoxy-5-fluorouridine. Six human breast cancer cell lines are tested.

Table 3

CI results at Fa₅₀ for select triplet combination of agents.

COMBINATION	MCF7/wt	MCF7/adr ⁺	BT474	SK-BR-3	HCC-1395	HTB-25
Mutually Non-Exclusive	CI-50	CI-50	CI-50	CI-50	CI-50	CI-50
Panobinostat+Carboplatin	0.7±0.0	0.8±0.1	0.6±0.1	0.4±0.1	0.5±0.1	0.8±0.1
Panobinostat+5'-DFUR	0.3±0.1	0.9±0.1	1.0±0.0	0.8±0.1	0.8±0.1	0.4±0.0
Panobinostat+Doxorubicin	1.6±0.2	0.6±0.1	0.9±0.0	0.3±0.1	0.3±0.0	0.5±0.1
Panobinostat+Docetaxel	0.9±0.1	0.4±0.0	0.3±0.1	0.3±0.1	2.0±0.1	0.5±0.1
Panobinostat+Fluvestatin	2.0±0.1	1.0±0.4	1.0±0.2	1.8±0.1	1.3±0.3	0.7±0.2
Panobinostat+Gemcitabine	0.4±0.1	0.9±0.0	1.3±0.1	0.6±0.1	0.4±0.1	0.8±0.1
Panobinostat+GW282974X	1.1±0.3	0.6±0.0	1.7±0.1	1.6±0.2	0.9±0.1	0.7±0.1
Panobinostat+Paclitaxel	0.7±0.1	0.9±0.1	1.2±0.2	0.8±0.1	1.2±0.1	0.5±0.1
Panobinostat+Topotecan	1.1±0.1	1.0±0.2	1.0±0.1	0.4±0.1	0.9±0.2	0.8±0.2
Panobinostat+Trastuzumab	1.0±0.4	0.7±0.1	1.6±0.2	1.6±0.2	0.6±0.1	0.6±0.1

CI < 1 is synergistic (green), 1 is additive (blue), and > 1 antagonistic (red). Values are means of studies ± standard deviation. PAN is panobinostat.